Cytomegalovirus infection reactivation in multiple myeloma patients administered proteasome inhibitor-combination therapy: A disproportionality analysis in a spontaneous reporting database

被引：0
|
作者：
Kaur, Gursimran [1 ]
Lukose, Lipin [1 ]
Thomas, Beulah E. [2 ]
Viswam, Subeesh Kulangara [1 ]
机构：
[1] Manipal Acad Higher Educ, Manipal Coll Pharmaceut Sci, Manipal, India
[2] Sparse Hosp, Bengaluru, Karnataka, India
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2022年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
1277
引用
收藏
页码：595 / 596
页数：2
相关论文
共 50 条
  • [11] Cytomegalovirus infection during daratumumab therapy in patients with newly diagnosed multiple myeloma
    Kikuchi, Taku
    Tsukada, Nobuhiro
    Kunisada, Kodai
    Nomura-Yogo, Moe
    Oda, Yuki
    Sato, Kota
    Takei, Tomomi
    Ogura, Mizuki
    Abe, Yu
    Suzuki, Kenshi
    Ishida, Tadao
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 120 (01) : 91 - 95
  • [12] Biomarkers of Cardiotoxicity Among Multiple Myeloma Patients Subsequently Treated with Proteasome Inhibitor Therapy
    Lendvai, Nikoletta
    Devlin, Sean
    Patel, Minal
    Knapp, Kristina Marie
    Ekman, Daniel
    Grundberg, Ida
    Chung, David J.
    Hassoun, Hani
    Koehne, Guenther
    Lesokhin, Alexander M.
    Landau, Heather
    Giralt, Sergio A.
    Korde, Neha S.
    Landgren, Ola
    BLOOD, 2015, 126 (23)
  • [13] A Retrospective Database Analysis of Treatment Pathways in US Medicare Patients with Multiple Myeloma Following Sequential Treatment with Lenalidomide and a Proteasome Inhibitor
    Boytsov, Natalie
    Cyhaniuk, Anissa
    Leung, Gary
    Wang, Feng
    Hogea, Cosmina
    Smith, Matthew Lee
    Mudumby, Pallavi
    BLOOD, 2021, 138
  • [14] The Efficacy and Safety Analysis of the Bendamustine, Pomalidomide, and Dexamethasone (BPD) Combination Treatment for Patients with Proteasome Inhibitor Intolerance and/or Relapsed Multiple Myeloma
    Zhao, Yiming
    Tian, Wanlu
    Jin, Fengbo
    Jiang, Lei
    Zhang, Rui
    Qian, Wei
    Xia, Leiming
    Yang, Mingzhen
    CURRENT PROTEOMICS, 2024,
  • [15] A Retrospective Database Analysis of Treatment Pathways in US Medicare Patients with Multiple Myeloma and Prior Exposure to Daratumumab, an Immunomodulatory Agent, and a Proteasome Inhibitor
    Boytsov, Natalie
    Cyhaniuk, Anissa
    Leung, Gary
    Wang, Feng
    Hogea, Cosmina
    Smith, Matthew Lee
    Mudumby, Pallavi
    BLOOD, 2021, 138
  • [16] Preemptive therapy for cytomegalovirus reactivation after daratumumab-containing treatment in patients with relapsed and refractory multiple myeloma
    Nakagawa, Ryo
    Onishi, Yasushi
    Kawajiri, Akihisa
    Onodera, Koichi
    Furukawa, Eijiro
    Sano, Sayaka
    Saito, Kei
    Ichikawa, Satoshi
    Fujiwara, Tohru
    Fukuhara, Noriko
    Harigae, Hideo
    ANNALS OF HEMATOLOGY, 2019, 98 (08) : 1999 - 2001
  • [17] Preemptive therapy for cytomegalovirus reactivation after daratumumab-containing treatment in patients with relapsed and refractory multiple myeloma
    Ryo Nakagawa
    Yasushi Onishi
    Akihisa Kawajiri
    Koichi Onodera
    Eijiro Furukawa
    Sayaka Sano
    Kei Saito
    Satoshi Ichikawa
    Tohru Fujiwara
    Noriko Fukuhara
    Hideo Harigae
    Annals of Hematology, 2019, 98 : 1999 - 2001
  • [18] Second-line Therapy for Patients with multiple Myeloma - almost 3 Years progression-free Survival with Combination of Isatuximab, Proteasome Inhibitor and Dexamethasone
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (1-2)
  • [19] New Therapy Option for pretreated Patients with multiple Myeloma Ixazomib: first oral Proteasome-Inhibitor available
    Luetke, Anja
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (1-2) : 66 - 66
  • [20] Ocular adverse events associated with BRAF and MEK inhibitor combination therapy: a pharmacovigilance disproportionality analysis of the FDA adverse event reporting system
    Huang, Shuohan
    Guo, Zihan
    Wang, Mengmeng
    She, Youjun
    Ye, Xuan
    Zhai, Qing
    Liu, Jiyong
    Du, Qiong
    EXPERT OPINION ON DRUG SAFETY, 2023, 22 (02) : 175 - 181
12345